

# Press Release

## ProStrakan Group plc

### ProStrakan Receives Approval for Adcal-D<sub>3</sub> Dissolve

Galashiels, Scotland, 3<sup>rd</sup> December, 2007 – ProStrakan Group plc (LSE: PSK), the international specialty pharmaceutical company, today announces that it has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for the launch in the UK of Adcal-D<sub>3</sub> Dissolve 1500mg/400IU Effervescent Tablets – a new, soluble formulation of its market-leading calcium vitamin D supplement, Adcal-D<sub>3</sub>.

Adcal-D<sub>3</sub> Dissolve is a branded calcium and vitamin D3 oral supplement, used as an adjunct to specific therapy for the treatment of osteoporosis.

The new formulation represents the latest phase in the brand development of Adcal-D<sub>3</sub> which, having established itself as the UK market leader in both value and volume terms in its original formulation, was supplemented by the launch of Adcal-D<sub>3</sub> Lemon chewable tablets earlier in 2007. In keeping with ProStrakan's philosophy of producing more patient-friendly medicines, the new formulation is also lemon flavoured and dissolves in water. It is believed that increasing the choice of tablet presentation may enhance patient compliance in this important disease area.

Adcal-D<sub>3</sub> Dissolve is ProStrakan's 46<sup>th</sup> marketing authorisation since the company's IPO in 2005 and will be launched in the UK in January 2008 in packs of 56 tablets at an NHS price of £4.99. Each tablet contains 1500 mg calcium carbonate (equivalent to 600 mg calcium) and 400 iu vitamin D<sub>3</sub> (equivalent to 10 µg of colecalciferol).

ProStrakan derived revenues of £6.6m from product sales of Adcal-D3 in H1 2007.

#### Further enquiries:

##### ProStrakan

Dr Wilson Totten, Chief Executive  
Paul Garvey, Chief Financial Officer  
Callum Spreng, Corporate Comms Director

Tel: +44 (0) 1896 664000

##### Financial Dynamics

David Yates/Ben Brewerton

Tel: +44 (0) 20 7831 3113

Notes to Editors:

ProStrakan

ProStrakan Group plc is a rapidly growing international specialty pharmaceutical company engaged in the development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets.

ProStrakan's head office and development facilities are situated in Galashiels in Scotland. EU-wide sales and marketing of ProStrakan's portfolio of products are handled by commercial subsidiaries in the UK, France, Germany, Spain and other EU countries. [www.prostrakan.com](http://www.prostrakan.com)